Literature DB >> 21782049

Bone mineral density, bone turnover markers and fractures in patients with indolent systemic mastocytosis.

Maurizio Rossini1, Roberta Zanotti, Patrizia Bonadonna, Anna Artuso, Beatrice Caruso, Donatella Schena, Decio Vecchiato, Massimiliano Bonifacio, Ombretta Viapiana, Davide Gatti, Gianenrico Senna, Annamaria Riccio, Giovanni Passalacqua, Giovanni Pizzolo, Silvano Adami.   

Abstract

OBJECTIVE: We systematically assessed bone mineral density (BMD), bone turnover markers (BTM), and fractures in a large cohort of patients with Indolent Systemic Mastocytosis (ISM).
METHODS: Eighty-two patients (mean age 48 years, 37 women) with ISM were studied. BMD was measured by dual X-ray absorptiometry at the lumbar spine and proximal hip. The serum markers of bone turnover included bone-specific alkaline phosphatase, C-telopeptides of type I collagen, and serum osteocalcin. Previous clinical fractures were registered and spine X-ray was obtained from all patients.
RESULTS: Three women were excluded for concomitant diseases associated to osteoporosis. Osteoporosis according with the WHO classification (T-score<-2.5) was found in 16 patients (20.0%) (7 females and 9 men). Mastocytosis-related low BMD (Z-score at either the spine or the hip<-2) was found in 3 women (9%) and 13 men (28%). The BMD was generally lower at the spine than at the hip. No significant correlation was observed between serum tryptase levels and T or Z-score BMD. One or more moderate or severe vertebral fractures were found in 17 patients (12 men); in 11 of them Z-score values were>-2 or not valuable at the spine. No significant difference was found in the prevalence of mastocytosis-related low BMD and/or vertebral fractures between patients with or without skin involvement. Two patients had radiographic and densitometric osteosclerosis-like characteristics. In osteoporotic patients higher, normal or lower serum BTM were found, without correlations with serum tryptase levels, while in patients with osteosclerosis both BTM and serum tryptase values were particularly increased.
CONCLUSIONS: Vertebral osteoporosis and fractures are frequent in patients with ISM. Spine X-ray and densitometric examination are warranted in all patients, also without skin involvement and particularly in males; Z-score other than T-score BMD must be evaluated. Patients with idiopathic osteoporosis should be evaluated for mast cell disease. Both high than low BTM can be observed in patients with osteoporosis while osteosclerosis is characterized by high bone turnover and serum tryptase levels.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21782049     DOI: 10.1016/j.bone.2011.07.004

Source DB:  PubMed          Journal:  Bone        ISSN: 1873-2763            Impact factor:   4.398


  20 in total

1.  Bone geometry, bone mineral density, and micro-architecture in patients with myelofibrosis: a cross-sectional study using DXA, HR-pQCT, and bone turnover markers.

Authors:  Sarah Farmer; Hanne Vestergaard; Stinus Hansen; Vikram Vinod Shanbhogue; Vikram Vinod Shanbhoque; Claudia Irene Stahlberg; Anne Pernille Hermann; Henrik Frederiksen
Journal:  Int J Hematol       Date:  2015-05-05       Impact factor: 2.490

2.  Bone mineral density and microarchitecture in patients with essential thrombocythemia and polycythemia vera.

Authors:  S Farmer; V V Shanbhogue; S Hansen; C I Stahlberg; H Vestergaard; A P Hermann; H Frederiksen
Journal:  Osteoporos Int       Date:  2016-10-13       Impact factor: 4.507

Review 3.  Management of endocrine disease: Secondary osteoporosis: pathophysiology and management.

Authors:  Faryal Mirza; Ernesto Canalis
Journal:  Eur J Endocrinol       Date:  2015-05-13       Impact factor: 6.664

4.  Increased osteoblast and osteoclast indices in individuals with systemic mastocytosis.

Authors:  S Seitz; F Barvencik; T Koehne; M Priemel; P Pogoda; J Semler; H Minne; M Pfeiffer; J Zustin; K Püschel; C Eulenburg; T Schinke; M Amling
Journal:  Osteoporos Int       Date:  2013-02-23       Impact factor: 4.507

Review 5.  Systemic mastocytosis revisited with an emphasis on skeletal manifestations.

Authors:  Antonio Leone; Marianna Criscuolo; Consolato Gullì; Antonella Petrosino; Nicola Carlo Bianco; Cesare Colosimo
Journal:  Radiol Med       Date:  2020-11-26       Impact factor: 3.469

Review 6.  Endocrine manifestations of systemic mastocytosis in bone.

Authors:  Loren Wissner Greene; Kamyar Asadipooya; Patricia Freitas Corradi; Cem Akin
Journal:  Rev Endocr Metab Disord       Date:  2016-09       Impact factor: 6.514

Review 7.  Prevalence, pathogenesis, and treatment options for mastocytosis-related osteoporosis.

Authors:  M Rossini; R Zanotti; G Orsolini; G Tripi; O Viapiana; L Idolazzi; A Zamò; P Bonadonna; V Kunnathully; S Adami; D Gatti
Journal:  Osteoporos Int       Date:  2016-02-18       Impact factor: 4.507

8.  [Severe therapy refractive osteoporosis : A rare differential diagnosis].

Authors:  M Gehlen; A D Lazarescu; C Hinz; N Schmidt; M Pfeifer; M Werner; H F Weidemann; M Schwarz-Eywill; A Maier
Journal:  Z Rheumatol       Date:  2016-09       Impact factor: 1.372

9.  Failure to generate bone marrow adipocytes does not protect mice from ovariectomy-induced osteopenia.

Authors:  Urszula T Iwaniec; Russell T Turner
Journal:  Bone       Date:  2012-12-12       Impact factor: 4.398

10.  Osteoporosis Caused by Systemic Mastocytosis: Prevalence in a Cohort of 8392 Patients with Osteoporosis.

Authors:  Martin Gehlen; Niels Schmidt; Michael Pfeifer; Subathira Balasingam; Michael Schwarz-Eywill; Anna Maier; Mathias Werner; Heide Siggelkow
Journal:  Calcif Tissue Int       Date:  2021-07-05       Impact factor: 4.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.